FGEN FibroGen, Inc

+0  (0%)
Previous Close 25.00
Open 25.00
Price To book 10.21
Market Cap 1.60B
Shares 63,888,000
Volume 333,255
Short Ratio 6.00
Av. Daily Volume 489,421

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from China trial released January 30, 2017. Primary endpoints met.
Roxadustat FG-4592
Anemia in chronic kidney disease
Phase 2 trial enrollment commenced January 2016. Continues to enroll as of November 2016.
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
Liver fibrosis
Phase 2 data due 3Q 2017.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 2 ongoing. Data due late 2017 or 1Q 2018.
Pamrevlumab (FG-3019)
Pancreatic cancer

Latest News

  1. FIBROGEN INC Financials
  2. FibroGen, Inc. :FGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  3. FIBROGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement
  4. Edited Transcript of FGEN earnings conference call or presentation 1-Mar-17 9:30pm GMT
  5. FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  6. FibroGen Reports Fiscal 2016 Financial Results
  7. Q4 2016 FibroGen Inc Earnings Release - After Market Close
  8. FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017
  9. FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  10. FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
  11. FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017
  12. Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen
  13. Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%
  14. FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  15. FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
  16. FibroGen (FGEN) Shares March Higher, Can It Continue?
  17. Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium
  18. Here Are Two Market Moving Biotech Catalysts To Watch This Week
  19. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  20. Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.